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a  b  s  t  r  a  c  t
The  B  vitamins  folic acid, vitamin  B12  and  B6  are  essential  for neuronal  function,  and  severe  deﬁciencies
have  been  linked  to increased  risk  of neurodevelopmental  disorders,  psychiatric  disease  and  dementia.
Polymorphisms  of  genes  involved  in B vitamin  absorption,  metabolism  and  function,  such  as  methylene
tetrahydrofolate  reductase  (MTHFR),  cystathionine   synthase  (CS),  transcobalamin  2 receptor  (TCN2)
and  methionine  synthase  reductase  (MTRR),  have  also  been  linked  to  increased  incidence  of  psychiatric
and  cognitive  disorders.  However,  the  effects  of  these  polymorphisms  are  often  quite  small  and  many
studies  failed  to show  any  meaningful  or consistent  associations.  This  review  discusses  previous  ﬁndings
from  clinical  studies  and  highlights  gaps  in  knowledge.  Future  studies  assessing  B vitamin-associated
polymorphisms  must  take  into  account  not  just  traditional  demographics,  but subjects’  overall  diet,
relevant  biomarkers  of  nutritional  status  and  also  analyze  related  genetic  factors  that  may  exacerbate
behavioral  effects  or  nutritional  status.lzheimer’s disease
utism
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. Introduction
Vitamin B12, B6 and folic acid play important roles in the devel-
pment, maintenance and function of the brain, and unsurprisingly,
here has been intense activity on elucidating the role of B vita-
in  deﬁciency in psychiatric and neurologic diseases. However, the
xact relationship between B vitamin status and risk of cognitive or
ehavioral disorders is unclear. For example, while epidemiological
tudies indicate B vitamin deﬁciency as a risk factor for cognition
roblems during normal aging, intervention studies have not pro-
uced robust effects (Tangney et al., 2009). One possible reason
or this lack of clarity may  be due to polymorphisms which regu-
ate B vitamin-associated biochemical pathways, either abrogating
eﬁciency symptoms, or providing protection in the context of low
ntake (Haggarty, 2007). This review will evaluate genes that reg-
late B vitamin function, which have also been linked to cognitive
ysfunction.
. Biochemistry and function of B12, B6, folic acid and
elated proteins
Vitamin B9 (folic acid or folate), B6 (pyridoxine and related
itamers) and B12 (also called cobalamin) play vital roles in
ethyl group donation for synthesis of proteins, lipids, nucleic
cids, neurotransmitters, and hormones. In cells, vitamin B12 and
olic acid are part of the methionine synthase (MS) complex that
educes homocysteine to methionine, which is then converted into
-adenosylmethionine (SAM), a crucial co-factor for 150+ methyl-
ransferases including glycine n-methyltransferase (GNMT) in the
ne carbon pathway (Fig. 1). After methyl group transfer, SAM
ecomes S-adenosylhomocysteine (SAH), which then becomes
omocysteine, via the enzyme SAH hydrolase (SAHH), thus com-
leting a cycle of methyl group transfer. Homocysteine also can
e converted into glutathione, an important antioxidant, via series
f intermediate steps requiring vitamin B6 as a cofactor and the
nzyme cystathionine beta synthase (CS).
Folate facilitates methionine synthesis from homocysteine by
cting as a cofactor for methylene tetrahydrofolate reductase
MTHFR) which converts 5,10-methylenetetrahydrofolate (CH2
HF) to 5-methyltetrahydrofolate (CH3 THF). CH2THF is generated
rom tetrahydrofolate by the enzyme serine methylhydroxytrans-
erase (SHMT), which also uses B6 as a co-factor. Sufﬁcient B12,
6 and folate therefore reduce levels of homocysteine, while deﬁ-
iency of B vitamins can cause hyperhomocysteinemia, which is
ssociated with increased risk of heart disease, cognitive problems
nd mood disorders (Almeida et al., 2008; Flickera et al., 2004).
evere deﬁciencies of B12, folate or B6 can lead to macrocytic or
ernicious anemia, syndromes characterized by fatigue, psychomo-
or, cognitive and mood deﬁcits (Selhub et al., 2009). Generally,
itamin B12 deﬁciency with sufﬁcient folate allows for production
f adequate SAM, while homocysteine levels remain high. Homo-
ysteine has been implicated in amyloid buildup, DNA damage, . . . . .  . . .  . .  . . .  . .  . . .  . . . . .  . .  . . . . . . .  .  . . . . . . .  . . . . . .  .  . . . .  . . . . .  .  . . .  .  .  .  . . . . . . . . . .  318
mitochondrial dysfunction, nuclear disintegration, and apoptosis
of neurons (Kruman et al., 2000). Adequate supplies of SAM are
crucial for maintenance of neurotransmitters and DNA synthesis
(Frankenburg, 2007).
Vitamin B12 also plays a role in conversion of methylmalonic
acid-CoA into succinic acid-CoA for use in the tricarboxylic acid
cycle. Speciﬁcally, the mitochondrial enzyme methylmalonyl Co-A
mutase (MUT) requires B12 (in the prosthetic form adenosylcobal-
amin) as a co-factor. Very low levels of B12 or mutations in MUT  may
lead to methylmalonic acidemia, a disorder associated with severe
brain damage, especially during development (Li et al., 2009).
While the many intersecting pathways of the methyl donor sys-
tem allow for some imbalance, too high or too low levels of B12, B6,
folate or their co-factors may  cause dysregulation of methyl donor
activity, and also buildup of toxic intermediates such as homocys-
teine and methylmalonic acid (Fenech, 2010). Moreover, imbalance
of SAM/SAH causes further inhibition of methylation reactions cru-
cial for cognitive function.
3. Clinical ﬁndings on B vitamin supplementation and
cognitive or mood disorders
A full discussion of the many intervention studies investigating
B vitamin modulation of behavior or cognition is beyond the scope
of this review. To summarize the ﬁndings thus far: combinations
of B vitamins, especially B6, B12 and folate, are more effective than
single vitamin treatment and the likelihood of a signiﬁcant effect
appears dependent on baseline imbalance of plasma homocysteine
and other methyl donor intermediates. However, with these stud-
ies there is a lack of consistency, especially for intervention studies
in aged populations, in dosage used, length of intervention, exper-
imental population, and assessments such as diet and lifestyle.
Three trials of B12 and folate supplementation (using different
doses and durations) in patients with dementia revealed no effect
on cognitive function (Aisen et al., 2008; Vital Trial Collaborative
Group, 2003). Yet another trial using mild cognitive impairment
(MCI) patients (29 subjects with memory complaints), 2 months
of folic acid increased attention and this effect was even stronger
in those with low baseline plasma folate (Fioravanti et al., 1997),
while other trials using folic acid only supplementation produced
no effects on cognition (Malouf and Grimley Evans, 2008).
The evidence for B vitamin supplementation and alleviation of
mood disorders is even weaker than that for cognitive decline,
especially for B12 and B6. While small pilot studies with specially
selected populations (patients with eating disorders, history of
stroke or cardiovascular disease) have shown some effects of folic
acid supplementation in monopolar or bipolar depression, system-
atic reviews indicate that the evidence is marginal (Sylvia et al.,
2013; Taylor et al., 2004).
In terms of physiological status, homocysteine levels are
decreased more by concurrent folic acid, B6 and B12 supplemen-
tation (Vogel et al., 2009), which may  partially explain why trials
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Fig. 1. Schematic illustration of one-carbon metabolism pathways where vitamins B6, B12 and folic acid are cofactors in the pathway. Serine methyltransferase (SHMT)
with  co-factor pyridoxal phosphate (PLP) transfers a methyl group onto tetrahydrofolate (THF) creating CH2-THF; MTHFR via cofactor ﬂavin adenine dinucleotide (FAD)
creates  CH3-THF. Methionine synthase reductase (MSR, also called MTRR) functionalizes methionine synthase (MS), which transfers a methyl group from homocysteine to
produce methionine where B12 is an essential cofactor. Methionine is converted into S-adenosylmethionine (SAM) via MATI/II. Glycine methyltransferase (GNMT) converts
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ystathionine.
hat supplement only one or the other often do not show posi-
ive results. Furthermore, baseline homocysteine levels in subjects
ppear to be linked to likelihood of cognitive deﬁcit, thus indicat-
ng a subpopulation (within highly heterogeneous disease groups
uch as depression, schizophrenia and dementia) more likely to
eneﬁt from supplementation. For example, a recent study supple-
ented 187 mild cognitive impairment (MCI) patients (age 70 or
bove) with vitamin B12, B6 and folic acid for 24 months showed
hat slower brain atrophy due to treatment was  correlated with
aseline plasma homocysteine levels (Smith et al., 2010).
In America where folate has been added to cereal grain products
or decades, deﬁciency is now very low (<1% of the population)
nd B12 is the predominant B vitamin deﬁciency (Selhub and
aul, 2011). Indeed, the ‘masking’ of B12 deﬁciency neurological
ymptoms by an abundance of folate also hinders diagnosis of
yperhomocysteinia, which contributes to higher rates of cognitive
roblems.
. Role of genetics in B vitamin deﬁciencies
Genetic makeup may  play an important role in which popula-
ions or subgroups will be more sensitive to B vitamin deﬁciency,
nd thus exhibit increased risk of mental disorders. Genetic dif-
erences may  also explain the prevalence of hyperhomocysteinia
nd methylmalonic acidemia, since most Western diets provide
dequate supplies of B12, B6 and folic acid. In fact, many cohort
tudies have shown that subjects’ genotype predicts cognitive func-
ion more than plasma B vitamin levels (Wilson et al., 2010). Genetic
akeup has been shown to inﬂuence levels of serum metabolites
n several genome wide association studies.
Aside from diet and genetics, plasma B vitamin levels are
ffected by many factors, such as age and environment, which mayrases and that SAH can be produced via other methyltransferases. Homocysteine
thyltransferase (BHMT). Cystathionine  synthase (CS) converts homocysteine to
ameliorate or intensify neurological disease in carriers of suscepti-
ble genotypes. Not surprisingly, a major challenge for researchers is
how to analyze genotype and interactions of genes that affect B vita-
min  bioavailability and function, while simultaneously integrating
information on individual nutrient proﬁles and health or patholo-
gies. Nonetheless, there is a growing view that B12, B6, folic acid
and associated intermediates must be monitored simultaneously
for appropriate nutrition recommendations in speciﬁc populations
or individuals.
5. B vitamin transport genes and deﬁciencies
Vitamin B12 has a complex transport process through the body,
beginning with binding to haptocorrin in the stomach, then to
intrinsic factor (IF) in the intestines, moving (while bound to IF) into
the bloodstream via cubilin receptors. Transcobalamin II (TCN2,
or holotranscobalamin when bound) transports B12 to peripheral
tissues. Studies in adults with neuropsychiatric disease have also
suggested the presence of an active transport mechanism into the
brain for vitamin B12, implicating the protein amnionless as a
possible transporter (Luder et al., 2008). Interestingly, B12 deﬁ-
ciency is frequently linked to poor absorption and metabolism
rather than low consumption. Moreover, supplementation of B12
does not always resolve deﬁciency, pointing to inefﬁcient or low
levels of B12-related enzymes or transport proteins. For instance,
in some individuals, B12 plasma levels may  be normal but B12
intermediates, such as holotranscobalamin, may be reduced due
to polymorphisms in the TCN2 gene. In addition, the TCN2 259R
allele is associated with lower holotranscobalamin levels, espe-
cially in the cerebral spinal ﬂuid of Alzheimer’s patients (Zetterberg
et al., 2003). Hence, transport proteins such as IF, transcobal-
amin II, cubilin, and haptocorrin are attractive targets for assessing
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Table  1
Genetic polymorphisms in B vitamin-related enzymes.
Gene Enzyme function Mutation effect Disease association
Folate hydrolase (FOLH1) C484T,
C1561T
Catalyzes the hydrolysis of
N-acetylaspartylglutamate to
glutamate and N-acetylaspartate
Unknown Depression, schizophrenia
(Roffman et al., 2013), dementia
(Kim et al., 2010)
Methylene tetrahydrofolate
reductase (MTHFR) C667T
Converts CH3 THF to CH2 THF T homozygote is less efﬁcient, thus
increased plasma homocysteine
Depression, schizophrenia, mental
retardation, dementia, bipolar
disorder
Methionine synthase (MTR)
A2756G
Converts homocysteine into
methionine
G allele may  increase
homocysteine levels
Dementia, depression
Fucosyltransferase 2 (FUT2)
(rs492602)
Immune response protein which
modulates B12 transport in the gut
GG carriers have higher plasma B12 Intelligence
Dihydrofolate reductase (DHFR)
19bp deletion in the intron1
(rs70991108)
Converts dihydrofolate into
tetrahydrofolate, using NADPH (for
purine synthesis)
Reduces protein expression by
eliminating Sp1 transcription
factor binding site
Intellectual ability
Methylenetetrahydrofolate
dehydrogenase (MTHFD1) G1958A
Converts
5,10-methylenetetrahydrofolate
and NADP+ into
5,10-methenyltetrahydrofolate
and NADPH
A allele increases plasma
homocysteine
Dementia
Cystathionine  synthase (CS)
844ins68
Converts serine and homocysteine
(with B6) into cystathionine
Insert increases plasma
homocysteine
Dementia, schizophrenia
Methionine synthase reductase
(MTRR or MSR) A66G
Converts SAH into SAM (with B12) G allele increases plasma
homocysteine
Mental retardation
Haptocorrin (TCN1) TC C776G Protects cobalamin from degration
in the stomach
Unknown Dementia
Transcobalamin II receptor (TCN2)
G775C
Binds cobalamin in the portal
circulation
More efﬁcient vitamin B12
transport and binding mechanisms
versus R allele homozygotes
Depression
Folate receptor 1 (FOLR1) G1816A Activated by folate to induce Double mutation (1816A and Tendency of double mutation
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aand G1841A signaling cascade
ognition–genotype relationships, since these genes are expressed
n brain tissues, but to our knowledge only TCN2 has been signiﬁ-
ant associated to incidence of neuropsychiatric disorders.
While some genetic diseases involving B12 metabolism have
ery severe effects on cognition, such as Immerlund–Grasbeck dis-
rder, mutations in this gene pathway appear to be rare and thus
eyond the scope of this review. Single nucleotide polymorphisms
SNPs) that are common (≥1% frequency) in the general popula-
ion have weak effects on B12 levels. Only about 3% of Western
opulations have been reported to have plasma B12 deﬁciency.
ree plasma B12, however, may  not indicate true deﬁciency and
12 complexed with transholocobalamin or B12-associated inter-
ediates (e.g., methylmalonic acid), may  be more informative of
ioavailability and functionality.
Folate found in food is often bound to glutamate or chains of
lutamic acids. Folate hydrolase (also called N-acetyl-l-aspartyl-l-
lutamate (NAAG) peptidase) cleaves NAAG into N-acetyl aspartate
NAA), which also releases free folate from glutamate. Folate hydro-
ase plays a vital role in regulating not only brain glutamate, but
lso free folate availability. The 484C SNP of the folate hydrolase
ene, FOLH1,  have been implicated in negative symptom severity
nd treatment response in schizophrenia (Roffman et al., 2013).
ree folate is transported into cells via various transporters, includ-
ng the reduced folate carrier, an organic anion antiporter that
xchanges 5-methyltetrahydrofolate. Polymorphisms of its encod-
ng gene, RFC-1,  are implicated in homocysteinemia (Lucock and
ates, 2006). Lastly, active folate is transported into the brain via
he folate receptor alpha, which is abundantly expressed in the
horoid plexus. Polymorphisms of the folate receptor alpha gene,
OLR1, have been reported in severe neurodevelopmental disor-
ers and some brain cancers, and also may  increase homocysteine
evels, especially in conjunction with other folate-related geno-
ypes (Grapp et al., 2012). Genes related to B vitamin transport and
etabolism, and their links to associated disorders are listed in
able 1, while Table 2 summarizes all the B vitamin genetic associ-
tion studies discussed in this review.1841A) possibly increases
homocysteine levels
(1816A and 1841A) to coincide
with dementia
6. Genetic contribution of B vitamin polymorphisms in
neurodevelopment
6.1. B vitamin deﬁciencies and neurodevelopment
During pregnancy, large amounts of vitamin B12, B6 and folic
acid are shunted to the fetus. Mothers deﬁcient in these micronu-
trients become more depleted in order to sustain appropriate levels
for brain development within the womb.  However, infants can
become B vitamin deﬁcient in the ﬁrst year of life, where long-
term deﬁciencies can cause neurological symptoms such as apathy,
tremor and fatigue (Finnell et al., 2008). Apathy and fatigue symp-
toms may  be due to folate’s role in neurotransmitter production,
while tremor symptoms appear to be related to the B12’s role
in myelination of neuronal axons, a prominent and rapid process
which occurs during infancy. Some populations in Indian and Latin
America become deﬁcient due to lack of protein in their diet, and
coupled with genotypes associated with poor B12 or folic acid
uptake, infants can show brain atrophy and mental retardation
(Black, 2008).
6.2. B vitamin polymorphisms and intellectual ability in general
populations
Only a few studies have analyzed B vitamin-related genes and
their association with general neurodevelopment. For example, the
incidence of neurodevelopmental disorders were higher in subjects
homozygous for the hypomorphic version of the methionine syn-
thase reductase (MTRR) A66G allele (Li et al., 2009) which has also
been linked to high levels of homocysteine in children (Aléssio et al.,
2007). Another gene which has recently been reported to affect
neurodevelopment is fucosyltransferase 2 (FUT2). The FUT2 pro-
tein is involved in production of gut antigens during infections, but
which also affects plasma levels of B12 via modulation of cobalamin
transporter expression in the gut (Hazra et al., 2008). Bonilla et al.
(2012) recently reported an association of maternal FUT2 rs492602
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Table 2
Studies investigating B12, B6 or folate related polymorphisms and behavior.
Reference Study design, subjects Measurement Effect
Development
del Río Garcia et al. (2009) 235 Mexican toddlers Bayley’s Scale (BSID)
Folate intake
MTHFR C667T genotype
Low folate intake (<400 mg/day) corr. with BSID in TT
carriers
Shaw et al. (2007) 100 retarded children 743 normal children Cognition test battery
MTHFR genotype
No association of C667T to intellectual ability
Dutta et al. (2011) 226 children with idiopathic intellectual disability and
parents
MTR A2756G, MTRR A66G, and DHFR rs70991108
genotype
Plasma folate, vitamin B6, vitamin B12, and cysteine
IID probands showed higher micronucleus frequency
and decreased vitamin B6; corr. w/MTR G allele and
micronucleus freq.
Fintelman-Rodrigues et al. (2009) 114 Brazilian mothers of Down’s children and 110
controls
CBS 844ins68, MTR  A2756G, RFC-1 G80A and TC
G776C genotype
No corr. between any of the maternal genotypes and
Down’s syndrome
Bosco et al. (2003) 92 Down’s children, 140 control subjects 63 case
mothers 72 age-matched control mothers
MTR A2756G MTHFR A1298C
MTRR A66G genotype
Plasma homocysteine, folate, vitamin B12
Homocysteine, MTR  2756 AG/GG and MTRR 66 AG
genotypes: increased risk of Down’s
Pas¸ ca et al. (2009) 147 Romanian autistic spectrum children Autism Diagnostic Interview, Revised Peabody Picture
Vocabulary Test, Ravens Colored Progressive Matrices,
and the Vineland Adaptive Behavior Scales;
MTHFR C667T genotype
MTHFR T allele associated with: direct gaze, current
complex body movements, a history of self-injurious
behavior, and current overactivity
Depression
Lewis et al. (2006) 3478 British women  MTHFR C667T genotype
History of depression, antidepressant use, and the
EuroQol mood questionnaire
Increased risk of depression diagnosis w/MTHFR TT
genotype
Lewis et al. (2012) 6809 pregnant British women  treated with folic acid MTHFR C667T genotype
Effect of folic acid suppl. on depression: Edinburgh
Postnatal Depression Scale
Folic acid during pregnancy decreased postpartum
depression incidence, esp. in MTHFR TT carriers
Almeida et al. (2005) 580 depressed Australian patients Beck Depression Inventory
Beck anxiety inventory (BAI) scores; MTHFR C667T
genotype; plasma B12 and homocysteine levels
Plasma homocysteine correlated with BDI scores, B12
and folate levels; no association between BAI and
MTHFR or homocysteine levels
Lanctt et al. (2010) 90 depressed Canadian subjects treated w/50 mg
citalopram
5HTTLPR, 5HT1A C1019G, 5HT2A T102C, MTHFR
C677T, BDNF val66met TPH2 G703T genotypes;
Hamilton Rating Scale for Depression (HAMD)
MTHFR TT genotype corr. w/treatment response from
citalopram
Yuan et al. (2008) 116 Chinese patients with geriatric depression and 80
healthy controls
Hamilton Rating Scale for Depression total score,
plasma homocysteine, MTHFR C667T genotype
Homocysteine corr. to depression, comorbid
cardiovascular disease and age of ﬁrst episode but no
effect of MTHFR
Gaysina et al. (2008) 1222 British patients with MDD, 835 control subjects MTHFR C667T genotype; depression incidence No signiﬁcant differences in genotype and depression
Hong et al. (2009) 178 depressed and 85 comparison elderly Chinese
subjects
White matter hyperintense lesion (WML)  gray matter
hyperintense lesion (GML) volume. MTHFR C667T
genotype; neurocognitive battery
MTHFR genotype assoc. w/age and WML  volume.
Genotype was not related to GML  volume, cognitive
function, or presence of depression
Naumovski et al. (2010) 118 elderly Russian participants (age 65–90 years) MTHFR C677T, Hamilton Depression Index, folic acid
indices
C677T MTHFR T assoc. w/Hamilton Depression Index;
thiol dipeptide Cys-Gly negatively associated to the T
allele
Lizer et al. (2011) 156 depressed American subjects and controls MTHFR C667T genotype; depression rating scale No assoc. of depression and MTHFR C667T genotype
Kim et al. (2009) 521 elderly east Asian subjects (community sample) 5-HTTLPR, MTHFR C677T genotype; depression
incidence
Number of somatic disorders and depression was
signiﬁcant in 5-HTTLPR s/s or MTHFR TT homozygotes
Lewis et al. (2006) 3478 British women  Indices of depression and MTHFR  C667T Increased risk of depressed diagnosis and MTHFR
C677T TT
Ye et al. (2011) 976 Puerto Rican adults, aged 45–75 years FOLH1 1561C>T FPGS, GGH, MTHFR MTR PCFT RFC1
and depression incidence and severity (CES-D)
FOLH1 TT and TC polymorphisms associated with
lower CES-D scores
Devlin et al. (2010) 82 pregnant, British women (supplemented w/1  mg/d
folate)
MTHFR C667T, BDNF V66M, 5-HTTLPR genotypes;
Edinburgh Postnatal Depression Scale (EPDS) and the
Hamilton Rating Scale for Depression (HAM-D)
MTHFR C677T allele was assoc. w/depression, poor
mood predicted less methylation in maternal and
neonatal 5-HTT promoter regions
Słopien et al. (2008) 83 Polish women with post-partum depression and 89
controls
MTHFR, MTR, MTHFD1 polymorphisms severity of
depression
MTR  GG genotype was shown increase the risk of
depression
Schizophrenia and bipolar disorder
Hill et al. (2011) 32 stable adult schizophrenia outpatients 12 week
add-on folate (2 mg/d)
Baseline to week 12 SANS total score; MTHFR C667T
genotype; treatment effects, plasma folate
T allele negative symptoms were more likely to
improve with increased serum folate
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Table 2 (Continued)
Reference Study design, subjects Measurement Effect
Yoshimi et al. (2010) 696 Japanese schizophrenic patients compared to 774
controls
MTHFR genotypes: C667T, rs17421511, rs17037396,
and rs9651118; incidence of schizophrenia
MTHFR genotypes (4 SNPs in total) did not contribute
to  risk of developing schizophrenia
Vares et al. (2010) 820 Scandinavian schizophrenic patients; 243 Chinese
high-risk families, with two or more affected siblings
MTHFR C667T, A1298C; age of onset of schizophrenia Lower age of onset with increased T-allele frequency in
Scandinavians. MTHFR 677T allele assoc. w/earlier age
at  onset in Chinese families
Ozbek et al. (2008) 197 bipolar patients, 278 relatives and 238 controls
(Turkish)
Homocysteine folate and B12 levels; MTHFR C677T
and A1298C genotype
Bipolar subjects and relatives with TT and/or AA and
AC  genotypes had elevated homocysteine, reduced
folate and B12 levels
Muntjewerff et al. (2011) 742 schizophrenia patients and 884 control subjects
(Dutch ethnicity)
MTHFR C677T, season of birth and schizophrenia
incidence
No MTHFR C667T assoc. w/schizophrenia risk
Vehof et al. (2012) 329 Dutch schizophrenic patients Clinical Global Improvement Impression scale (CGI-I);
DRD2: TaqI A141C; DRD3: Ser9Gly; HTR2A: T102C,
His452Tyr; HTR2C: Cys23Ser; COMT: Val158Met;
MTHFR: C677T genotype
Gly-carriers and T-carriers, showed more clinical
improvement on the CGI-I due to antipsychotics
Roffman et al. (2008a) 200 outpatient schizophrenics (American) MTHFR C677T, A1298C genotype; negative, positive
symptoms Positive and Negative Syndrome Scale
(PANSS), folate status
Patients homozygous for the 667T allele, serum folate
levels correlated with negative symptom severity
Roffman et al. (2007) 200 outpatients with chronic schizophrenia
(American)
MTHFR C667T; Verbal Fluency Test (VFT), Wisconsin
Card Sort Test (WCST), and California Verbal Learning
Test (CVLT)
T/T subjects → greater deﬁcits on the VFT and WCST
Roffman et al. (2011a,b) 18 schizophrenic patients (American) Bilateral ACC and the substantia nigra activation while
performing an attention task
MTHFR 667T allele carriers had less error-related
activation than C/C patients
Roffman et al. (2008b) 185 schizophrenic subjects (American) COMT) Val108/158Met MTHFR C677T; Wisconsin Card
Sort Test (WCST)
COMT Val alleles and the MTHFR T alleles associated
with more preservative errors in the WCST
Tsutsumi et al. (2011) 407 Japanese schizophrenia cases and 384 controls DRD2, DRD4, GRIN2B, TPH1, MTHFR, and DTNBP1 No signiﬁcant association of the genetic risk-index (7
polymorphisms) and disease
Peerbooms et al. (2012) 98 patients with non-affective psychotic disorder and
118 controls (Dutch)
Daily life stress via experience sampling method
(ESM); MTHFR C677T, MTHFR A1298C, and
COMTVal158Met genotype
MTHFR 677 T-allele, COMT Met/Met individuals
displayed the largest increases in psychotic symptoms
in reaction to ESM stress
Golimbet et al. (2009) 1135 patients, 626 controls and 172 families, Russian
ethnicity
CBS 844ins68 polymorphism, schizophrenia incidence 844ins68 associated with decreased schizophrenia
risk, attention and auditory evoked potentials
Cognition  in aged populations
Tsai et al. (2011) 356 elderly Chinese males Cognitive Abilities Screening Instruments (CASI),
Wechsler Digit Span Task tests; MTHFR C677T
genotype
TT and CC carriers performed worse on the CASI than
C/T carriers
Seripa et al. (2003) 124 American AD patients, 97 controls; 126 Italian AD
cases, 106 controls, 1232 community-based subjects
(>65 years)
MTHFR C677→T and ACE insertion/deletion (I/D) No association was found for the ACE and MTHFR
polymorphisms with age at onset, disease duration
and MMSE  score at observation
Religa et al. (2003) 99 AD patients, 98 subjects with MCI  and 100 healthy
subjects
ApoE and MTHFR C677T, plasma homocysteine levels
and vitamins (B12 and folic acid) concentrations
For AD, interaction of homocysteine with MTHFR T/T
genotype and low folate levels; ApoE4 allele corr. to
AD but not any other biomarker
Durga et al. (2006) 818 Dutch subjects (50–70 years) Neuropsychological tests, folate and associated
markers; MTHFR C677T
MTHFR 677TT genotypes performed better on
sensorimotor tasks than CC/CT; low erythrocyte folate
assoc. w/complex speed and memory tasks
Flickera et al. (2004) 299 British men, mean age 79 APOE and MTHFR C667T; plasma amyloid, APP, APOE
homocysteine; Geriatric Depression Scale-15,
cognition test battery
no effects of MTHFR on any biomarker; APOE epsilon4
assoc. w/cognition and depression
Elkins et al. (2007) 6653 older American women MTHFR C667T; Mini-Mental State Examination
(mMMSE), the Digit Symbol Substitution Test (DSST),
Trails B test; homocysteine and folate status
MTHFR C677T no assoc. to lower baseline performance
or decline. High homocysteine and TT genotype
associated w/DSST
Ford et al. (2012) 4227 Australian men  aged 70–89 years Homocysteine; MTHFR C667T genotype; lifestyle
factors, Telephone Interview for Cognitive Status
(TICS), and clinical variables w/postal and face-to-face
assessments
High homocysteine was  linked to incidence of
dementia, no assoc. of MTHFR allele
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and offspring IQ in a longitudinal study of parents and children,
regardless of maternal B12 intake. Interestingly, FUT2 rs492602 is
a key genetic modulator of B12 deﬁciency (approximately 3% of
Western populations carry the FUT2 allele correlated to low B12)
(Black, 2008). Lack of B12 to the developing brain may have lifelong
effects in what appear to be intellectually normal children. SNPs
in several genes related to B12 metabolism, i.e., methionine syn-
thase (MTR), methylene tetrahydrofolate reductase (MTHFR) and
cystathionine  synthase (CˇS) and their association with cognitive
ability as measured by IQ tests were also studied. The CˇS 844ins68
allele, which decreases efﬁciency of the enzyme, was signiﬁcantly
under-represented in children with high IQ (Barbaux et al., 2000).
Although brain CS expression is only 20% of that of expression
in the periphery, this ﬁnding suggests that metabolism of homo-
cysteine via CS may  be an important factor for optimal brain
development.
The MTHFR C677T polymorphism has attracted great interest
since the T variant causes a thermolabile form of MTHFR, which
requires much higher levels of folate than the C variant to stabilize
the binding of ﬂavin-adenosine-dinucleotide (FAD). Thus carriers of
the T allele are more susceptible to folic acid deﬁciency, as well as
developmental syndromes and later psychiatric illness. MTHFR has
been analyzed or discussed in over 2500 publications (PubMed) in
many diverse phenotypes and conditions. For example, one recent
study investigated the MTHFR C677T polymorphism by measuring
cognition in 235 Mexican toddlers (via the Bayley’s Scale) and asso-
ciating scores with either nutritional status or genotype. Deﬁciency
of vitamin B12 was  negatively associated with mental development
while low dietary intake of folate (<400 mg/day) reduced Bailey’s
Scale scores in children of TT genotype carriers only (del Río Garcia
et al., 2009).
With regard to more intellectually disabled children, no associa-
tion of the MTHFR genotype or degree of impairment in a report that
examined 100 severely mentally retarded children (i.e., without tri-
somies) compared to 743 normal controls (Shaw et al., 2007). In a
follow up study, 226 children with idiopathic intellectual disability
(IID) were tested, along with their nuclear families, for associations
to B12 and folate cycle gene polymorphisms (Dutta et al., 2011).
Speciﬁcally, signiﬁcant differences in genotype frequencies were
observed for the polymorphisms: MTR A2756G, MTRR A66G, and
DHFR rs70991108 in IID subjects as compared to controls.
6.3. B vitamin polymorphisms and Down’s syndrome
Due to MTHFR’s role in methyl donation, several studies have
examined the relationships between the C677T polymorphism and
risk of having a Down’s syndrome (DS) child. They have shown that
having one of the ‘risk’ alleles (C677T or A1298C MTHFR  polymor-
phic variants) increases one’s chance of having a Down’s syndrome
baby while two risk alleles further increases incidence (Martínez-
Frías, 2008). Another study using a separate set of polymorphisms:
CˇS 844ins68, MTR A2756G, reduced folate carrier (RFC-1) G80A
and transcobalamin (TCN) G776C in 114 mothers of Down’s chil-
dren and 110 matched controls found no correlations, indicating
that offspring genotype may  be more important than maternal
genotype at these alleles (Fintelman-Rodrigues et al., 2009). A
study examining the interactions of B12-related alleles found that
the MTR AG genotype was a signiﬁcant risk factor for having a
Down’s syndrome child or being a Down’s syndrome case (Bosco
et al., 2003). In addition, carriers of both the MTR  A2756G and the
MTRR A66G genotypes had even higher risk of having a DS child.
Additionally, in a follow up study researchers found that plasma
homocysteine, the MTHFR 677T allele and transcobalamin (TCN)
776G allele were negatively associated with IQ in Down’s syndrome
patients (Guéant et al., 2005).
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.4. B vitamin polymorphisms and autism
Folic acid supplementation has been linked to lower incidence
f autism in a cohort of over 85,000 children (Surén et al., 2013).
 vitamin-related genes have also been analyzed in subjects with
utism or autistic spectrum behaviors. In autistic disorder and
ervasive development disorder (PDD) groups, plasma levels of
ethionine, cysteine and total blood glutathione were found to
e reduced, while plasma homocysteine, vitamin B12, and folate
ere in the normal range (Pas¸ ca et al., 2009). The results of the
THFR gene analysis showed a trend of the 677T allele as slightly
ore prevalent in AD patients. Another group, using data from the
utism Genetic Resource Exchange (AGRE), analyzed symptomol-
gy as deﬁned by the Autism Diagnostic Interview—Revised (ADI-R)
nd found that the following four behaviors were positively asso-
iated with the MTHFR T allele: poor direct gaze, current complex
ody movements, a history of self-injurious behavior, and current
veractivity (Goin-Kochel et al., 2009).
In conclusion, the above ﬁndings point to a meaningful role of
 vitamin-related genes in select neurodevelopmental syndromes.
eplicating these associations will be challenging due to the low
requency of the risk alleles of MTHFR,  MTR, MTRR,  and DHFR in some
opulations (Martínez-Frías, 2008). For example, MTHFR C677T
nd MTRR A66G polymorphisms are associated with a greater risk
f having a child with DS in North America, Ireland, and The
etherlands, but not in Sicily or France (Guéant et al., 2003), possi-
ly due to the differential incidence of these alleles in the general
opulations of these regions. Interestingly, a recent pilot interven-
ion study of leucovorin (folinic acid) in autistic children displaying
olate receptor auto-antibodies improved several behavior indices
Frye et al., 2013). These results support the notion that bioactive
olate is deﬁcient in some cases of autism, and may  possibly be
nﬂuenced by genes involved in one carbon metabolism. Future
tudies require multivariate analysis of environmental, physiologi-
al, nutritional and genetic data of parents and offspring to generate
risk intersections’ of these factors.
. Genetic contribution of B vitamin polymorphisms in
epression
.1. B vitamin bioavailability and depression
Low B vitamin status has long been linked to depressive behav-
or, especially subjects with lethargic, apathetic symptomology
Semmes, 2005). S-adenosyl methionine (SAM) has been repeat-
dly shown as just as effective as many currently prescribed
ntidepressants (Coppen and Bolander-Gouaille, 2005). How SAM
an function as a neuroactive agent is not clear since a SAM cell
embrane transporter has not been identiﬁed. SAM could be trans-
orted across cellular membranes by one of the many members of
he organic ion and ATP cassette transporter families or via analogs
f mitochondrial SAM transporters, but this has not been proven
n the literature (http://omim.org/entry/611037). More bioavail-
ble forms of folate and B12, 5-methyltetrahydrofolate (also called
ethylfolate) and methylcobalamin, have also been touted as
epression therapies (Coppen and Bolander-Gouaille, 2005).
.2. General depressive disorders
Although B vitamin deﬁciency is linked to depression incidence,
t has proved difﬁcult to show a signiﬁcant association of B vitamin
olymorphisms. In fact, even highly publicized ‘risk’ alleles such
s the ‘short’ version of serotonin transporter promoter (5-HTTLPR)
as not been conclusively linked to depression incidence, probably
ecause of the heterogeneous nature of the disease. Some strong,havioral Reviews 47 (2014) 307–320
though still debated, evidence has been generated for association
of the MTHFR C677T polymorphism with depression.
While GWAS studies have failed to signiﬁcantly link any poly-
morphisms to depression, two meta-analyses of 20 and 26 studies
respectively showed a signiﬁcant effect from the MTHFR C677T
polymorphism on incidence of depression (López-León et al., 2008;
Wu et al., 2013). However, there may  be ethnicity consideration
that add complexity to these ﬁndings, since another meta-analysis
assessed the inﬂuence of the MTHFR C677T polymorphism in 5
studies and concluded that the dominant allele (T) had an asso-
ciation with depression in Asian but not Caucasian populations
(Zintzaras, 2006). In contrast a large study of 3478 European
women found a strong association between the MTHFR C677T geno-
type and three indicators of depression (history of depression,
antidepressant use, or the EuroQoL mood questionnaire). In the
same article, a meta-analysis of eight studies also indicated a strong
link of the T allele to depression risk (Lewis et al., 2006).
In order to clarify the association of MTHFR genotype in depres-
sion several groups have used symptom severity or treatment
response as co-variates. A recent study involving 402 depressed
subjects and 600 controls (Han Chinese ethnicity), found a posi-
tive association between high Hamilton Rating Scale for Depression
(HAMD)-17 scores and TT or CT genotypes (Li et al., 2010). Another
study that examined 90 subjects with depression secondary to
traumatic brain injury found that those with MTHFR TT geno-
types predicted greater treatment response with 50 mg citalopram
(Lanctt et al., 2010). However, many individual studies have failed
to show a MTHFR C677T association with depression incidence. For
instance, Almeida and colleagues reported that for 580 depressed
patients the Beck Depression Inventory (BDI) score of TT geno-
type subjects was  unchanged compared to other MTHFR genotypes
(Almeida et al., 2005), although plasma homocysteine strongly cor-
related with BDI scores, as well as B12 and folate levels. Two  other
studies using large cohorts of depressed patients and controls found
no association of the MTHFR C677T polymorphism to disease inci-
dence (Gaysina et al., 2008; Lizer et al., 2011). However, these
studies did not use co-variate data such as symptom severity or
progression to identify more complex interactions of MTHFR alleles
and mood. One approach successfully used to discern such interac-
tions demonstrated that childhood trauma and MTHFR TT genotype
predicted depression risk (Lok et al., 2013).
7.3. Geriatric depression
Studies focusing on depressed elderly subjects have found sig-
niﬁcant associations with plasma B12 levels, possibly due to a
higher rate of age-related gastritis which decreases intrinsic factor
(IF) expression causing reduced B12 uptake (Tiemeier et al., 2002).
Age-induced B12 deﬁciencies make it more difﬁcult to demonstrate
genetic linkage to depression in older subjects. In a study of 116
patients with geriatric depression plasma homocysteine was signif-
icantly higher than compared to healthy controls, and there was a
correlation with the age of ﬁrst episode and comorbid cardiovascu-
lar disease with homocysteine levels (Yuan et al., 2008). However,
there were no signiﬁcant differences in the MTHFR C677T polymor-
phism genotypes and alleles between the patients and the healthy
controls. This ﬁnding was  supported by a later study performed
with elderly Chinese depressed patients and age matched controls,
where the 677T allele was not more frequent in depressed subjects
or related to cognition or gray matter hyperintensity volume (Hong
et al., 2009).
Some studies have found some positive genetic relationships to
geriatric depression by using novel biomarkers or associated health
conditions as covariates. One of the earliest studies on the associ-
ation of MTHFR and geriatric depression found higher incidence of
the T allele subjects with vascular risk factors (Hickie et al., 2001).
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nother geriatric depression study showed that the C677T MTHFR
 allele was associated with higher scores in the Hamilton Depres-
ion Index (HADS), while plasma thiol dipeptide Cys-Gly, which is a
roduct of folate and glutathione metabolism, was negatively asso-
iated to the T allele (Naumovski et al., 2010). Lastly in 538 elderly
ast Asian subjects the MTHFR TT genotype was  associated with
eneral somatic morbidity and incidence of depression (Kim et al.,
009).
.4. Pregnancy-related depression
Folic acid supplementation for pregnant women is now a well-
stablished preventative measure against neural tube defects, but
ore recently epidemiological data on B vitamin intake and post-
artum depression has emerged, with some interactions toward
enotypes (Black, 2008; Lewis et al., 2012; Selhub and Paul, 2011).
olic acid supplementation during the last two trimesters had no
ffect on development of depression 0–8 months after delivery, yet
id have a slight effect 21 months postpartum, and this effect was
ntensiﬁed in women with the MTHFR C677T TT genotype (Lewis
t al., 2012). The MTHFR C677T allele also was associated with
reater depressed mood during pregnancy and poor mood pre-
icted less methylation in both maternal and neonatal 5-HTTLPR
romoter regions (which regulates expression of the serotonin
ransporter) (Devlin et al., 2010). Surprisingly, few depression asso-
iation studies have investigated the interaction of polymorphisms
elated to monoamine function since B vitamins are involved in
onoamine metabolism.
Few studies have assessed depression linkage to polymorphisms
n other B vitamin interacting genes. Ye et al. studied poly-
orphisms in folate polyglutamate synthase (FPGS), -glutamyl
ydrolase (GGH), methionine synthase (MTR), proton-coupled
olate transporter (PCFT), and reduced folate carrier 1 (RFC1) genes
n 976 Puerto Rican adults, aged 45–75 years, and none of the
ariants were related to depression (Ye et al., 2011). The folate
ydrolase (FOLH1) C1561T polymorphism was signiﬁcantly asso-
iated with lower CES-D score and TT and TC genotypes were less
ikely to report depressive symptoms. A study of 83 Polish women
ith post-partum depression and 89 controls investigated the asso-
iation of MTHFR,  MTR, and MTHFD1 polymorphisms according to
he severity of depression. After stratiﬁcation of symptoms, the MTR
G genotype was shown increase the risk of depression 5-fold,
hile MTHFR and MTHFD1 genotypes had no inﬂuence (Słopien
t al., 2008).
. Genetic contribution of B vitamin polymorphisms in
ipolar disorder and schizophrenia
.1. Schizophrenia incidence and MTHFR polymorphisms
Genetic analysis of B vitamin-related genes has been more
revalent in studies schizophrenia or bipolar disease, where there
s estimated heritability of 80%, as opposed to unipolar depression,
here heritability is estimated to be around 40% (Stringer et al.,
011). While schizophrenia and bipolar depression are less het-
rogeneous diseases compared to unipolar depression, the more
obust heritability results may  be due to the higher severity of
ognitive and behavioral problems in the former diseases. Bet-
er phenotyping makes it easier to ﬁnd associations and the best
xample is MTHFR C677T. In one recent meta-analysis of MTHFR
677T (n = 29,502) researchers found a signiﬁcant associations in
chizophrenic and bipolar but not unipolar depressive patients.
owever, unipolar depression association studies have not been
idely performed (Peerbooms et al., 2011).havioral Reviews 47 (2014) 307–320 315
While a majority of single cohort studies have found pos-
itive polymorphism associations mostly with MTHFR  alleles,
meta-analyses report contradictory ﬁndings, which may  be a con-
sequence of inclusion criteria for subjects and a greater range of
ethnicities in recent studies. No signiﬁcant association between
either allele of the MTHFR C677T polymorphism and the risk
of developing bipolar disorder, depression or schizophrenia was
found in a meta-analysis of 10 studies (Zintzaras, 2006). In
contrast, a more recent meta-analysis investigated the relative
associations of 20 different polymorphisms previously linked to
schizophrenia and found that MTHFR C677T was one of the 6
that showed a signiﬁcant association (Allen et al., 2008). In this
same meta-analysis, which used a database of over 1000 genetic
association studies (‘SzGene’), other well-known genes such as
apolipoprotein E (APOE), dopamine 2 receptor (D2DR) and catechol-
O-methyltransferase (COMT)  were reported to have no effect on
incidence of schizophrenia (Allen et al., 2008). Lastly, the authors
remarked that these ﬁndings supported an epigenetic role in these
diseases.
The association of MTHFR C677T and schizophrenia is still
controversial. In a meta-analysis of studies using east Asian
populations, the population attributable risk was only marginally
signiﬁcant for C677T and schizophrenia, as well as bipolar depres-
sion (i.e., increased risk for T allele carriers) (Shi et al., 2008).
However, in a genome wide association study (GWAS) of 696
Japanese schizophrenic patients compared to 774 controls, impu-
tational analysis showed no relationship of MTHFR genes (4 SNPs
in total) to risk of developing schizophrenia (Yoshimi et al., 2010).
Lastly, a ‘risk index’ model was used to study whether 384
schizophrenic patients exhibited a higher incidence of polymor-
phisms previously associated with schizoid disorders by adding
together the number of genetic risk factors (methylenetetrahydro-
folate reductase; MTHFR, dopamine 2 receptor; DRD2,  dopamine 4
receptor; DRD4, glutamate receptor ionotropic NMDA subunit 2b;
GRIN2B, tryptophan hydroxyolase; TPH1, and dystrobrevin binding
protein 1; DTNBP1) (Tsutsumi et al., 2011). However, the ‘risk index’
was similar between patients and controls, belying the notion that
schizophrenia incidence can be predicted by a limited collection of
risk genes in the absence of behavioral or biochemical co-variates.
8.2. MTHFR polymorphisms, biomarkers and behavioral
phenotypes
More in-depth analyses of schizophrenia risk and MTHFR have
examined familial genotypes, nutritional status, age of onset and
season of birth as co-variates. The C677T polymorphism signiﬁ-
cantly affected age at onset of schizophrenia, with lower age of
onset coinciding with increased T-allele frequency in 820 Scandina-
vian schizophrenic patients (Vares et al., 2010). In the same study,
the MTHFR T allele was  associated with earlier age at onset than
siblings homozygous for the C allele in group of high-risk families
of Chinese descent (two or more affected siblings, n = 221). Lastly,
a study examining season of birth and incidence of schizophrenia
found no association of MTHFR C677T genotypes and schizophrenia
risk in Dutch subjects (Muntjewerff et al., 2011).
Inclusion of brain imaging and challenging cognition tasks have
also been used to increase genetic association robustness. Rothman
and associates have extensively analyzed the relationship between
MTHFR, brain activation and cognition in schizophrenic patients. In
an initial study, this team showed that the MTHFR 677T allele was
associated with worse executive function using a Verbal Fluency
Test and a Wisconsin Card Sort Test (WCST) (Roffman et al., 2007).
Subsequent studies from this group used fMRI to analyze activa-
tion of two dopaminergic regions, the bilateral anterior cingulate,
and the substantia nigra in 18 schizophrenic patients performing
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ttention task. They found that MTHFR 677T allele carriers had less
rror-related activation than C/C patients (Roffman et al., 2011a).
The MTHFR polymorphism C677T also appears to play a
ole in reducing positive symptoms via antipsychotic treat-
ent. Six polymorphisms were investigated for association to
ntipsychotic efﬁcacy in 329 Dutch patients using the Clinical
lobal Impression—Improvement (CGI-I) scale to assess behav-
oral changes. Those individuals with the MTHFR T allele showed
ore improvement with atypical antipsychotics such as olanzap-
ne, which may  be linked to the previous associations of this allele to
ehavioral disturbances (Vehof et al., 2012). However, better treat-
ent response may  also couple with other physiological changes,
ince a separate study revealed that schizophrenic subjects with the
THFR T allele had higher risk of metabolic syndrome after antipsy-
hotic treatment (Ellingrod et al., 2012). Interestingly, a study with
00 schizophrenia patients showed a positive relationship of folic
cid status, MTHFR 677T allele, and reduced negative symptoms
Roffman et al., 2008c). This 3-way relationship was  supported
y results in 32 schizophrenia patients who received either folic
cid (2 mg/d) or placebo, where a reduction in negative symptoms
as noted in MTHFR T allele carriers whose folate also rose from
reatment (Hill et al., 2011).
.3. Epistatic contribution of COMT to MTHFR
COMT,  the enzyme which breaks down dopamine, has long
een implicated in schizophrenia and is also a major methyl donor
nzyme. Carriers of both COMT Val alleles and the MTHFR T alleles
howed more preservative errors in the WCST (Roffman et al.,
008b). In a supporting study with 79 schizophrenia patients and
0 controls, the T allele was associated with decreased prefrontal
orking memory activation in dopaminergic brain regions, adding
redence that the MTHFR T allele was associated with decreased
opamine function (Roffman et al., 2008a). Interestingly, the MTHFR
T and COMT Val/Val genotypes were associated with reduced pre-
rontal activation in schizophrenics, and with CC and Met/Met
enotypes in controls. In subjects with MTHFR T and COMT Val
lleles, prefrontal cortex dopamine levels were correlated with
oor information processing and working memory (Roffman et al.,
008a). COMT Val/Met and MTHFR C677T polymorphisms are also
ssociated with reactivity due to daily life stress. Anxiety was signif-
cantly increased in 98 schizophrenics homozygous for COMT Met
nd MTHFR T alleles, while no effects of genes were seen in 100
on-schizophrenic controls (Peerbooms et al., 2012).
A recent review addressed the COMT Val/Met allele polymor-
hism and concluded that optimal functioning of dopamine may
ave a U-shaped curve where too little or too much causes dys-
unction. MTHFR may  exacerbate a COMT-mediated imbalance of
opaminergic signaling (Witte and Flöel, 2012). The above fam-
ly of association studies point to a more mechanistic exploration
f MTHFR C677T cognitive roles by revealing epistatic interactions
hich may  be modiﬁable via carefully controlled supplementation.
nalysing COMT polymorphisms in combination with other B vita-
in  pathways may  be efﬁcacious since the methyl transfer function
f this enzyme is so tightly linked to B vitamin sufﬁciency. Other
enes shown to have epistatic relationships with COMT are DISC1,
GS4 and BDNF (Nicodemus et al., 2007; Witte and Flöel, 2012),
here cognitive ability is enhanced or impaired via particular gene
ombinations.
.4. Cystathionine beta-synthaseCompared to the extensive analyses of MTHFR interactions
ith schizophrenia, very few studies have examined other B-
itamin associated genes. The 844ins68 polymorphism of the
ystathionine beta-synthase (CˇS) was associated to increasedhavioral Reviews 47 (2014) 307–320
risk of schizophrenia and also to changes in attention and auditory
evoked potentials (Golimbet et al., 2009, 2010). A mouse model
of CˇS overexpression was  shown to have improved hippocampal
signaling versus wild-type mice, while mice deﬁcient in CS
display higher SAHH and Dyrk1A, a kinase involved in methylation
with putative roles in Down’s syndrome cognitive dysfunction
(Becker and Sippl, 2011). Lastly, Roffman et al. recently published
a study showing that MTR 2756A and FOLH1 484C contributed
more potently to negative symptom severity than MTFHR C677T
genotype (Roffman et al., 2011b).
9. Cognitive decline/dementia
Unlike several developmental and psychiatric disorders, no
meta-analysis has been reported for MTHFR or any other B vitamin-
related SNPs for cognitive decline. While the contribution of B
vitamins to brain aging has been demonstrated frequently, asso-
ciation of polymorphisms in other B vitamin genes with cognitive
decline have not been found, perhaps because of confounding of
age-related decreases in B vitamin absorption and metabolism.
However, in cognitive decline studies there has also been more
attention to not just MTHFR polymorphisms but also other genes
associated with Alzheimer’s incidence, such as APOE.
9.1. MTHFR and cognitive decline
Recent reports describe the use of several B vitamin biomarkers
and genes to identify possible synergies of the MTHFR polymor-
phism with more extensive physiological data. For instance, Religa
and colleagues found that only Alzheimer’s patients with high base-
line homocysteine and low plasma folate had higher incidence
of the MTHFR TT genotype (Religa et al., 2003). This same study
also indicated that APOE-epsilon4 alleles were independently dis-
tributed in such patients (Religa et al., 2003) with no apparent
epistatic relation to MTHFR.  A found positive association of MTHFR
TT genotype and ability on a psychomotor task in 818 elderly
subjects but not other types of cognition (Durga et al., 2006). In
contrast Flickera et al. examined APOE and MTHFR C677T status,
and plasma amyloid, APP, APOE and homocysteine in 299 elderly
men, and found no association with MTHFR for any variable. In
contrast, APOE epsilon4 strongly predicted cognition and depres-
sion (Flickera et al., 2004). B12 status was  positively associated
with cognition as assessed by the MMSE  performance the asso-
ciation was stronger in those with APOE epsilon 4 genotype (Feng
et al., 2009). Conversely, Abello showed that Italian AD patients had
higher than average homocysteine levels which were potentiated
by MTHFR T and APOE epsilon 4 status (Anello et al., 2004). In a study
conducted in China, 356 elderly males with no major neurological
disorders were assessed by the Cognitive Abilities Screening Instru-
ments (CASI) and the Wechsler Digit Span Task tests and tested for
MTHFR C677T genotype; TT and CC homozygotes did worse on the
CASI compared to C/T carriers, suggesting that a median level of
MTHFR activity may be most beneﬁcial for cognition (Tsai et al.,
2011). High homocysteine and MTHFR 677T were associated with
intima-media thickness, a physiology indicative of microvascular
damage (Gorgone et al., 2009).
Two longitudinal studies showed nominal association of MTHFR
TT genotype status with measures of decline. Positive correlations
of the TT genotype were associated with lower scores on the Digit
Symbol Substitution Test, Trails B test and with annual decline on
the Mini-Mental State Examination (MMSE) (Elkins et al., 2007).
Baseline homocysteine predicted risk of dementia over a 10 year
period in 4337 healthy aged men  (Ford et al., 2012). However, the
study was  underpowered for conclusive understanding of MTHFR
polymorphisms on development of dementia.
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On the whole it appears that effects of MTHFR on age-related
ognition are subtle and inconsistent.
.2. TCN2, MTR, MTHFD1, GCPII
Garrod and colleagues (2008) found a relationship of high
omocysteine and low holotranscobalamin to poor cognitive func-
ion. TCN2 776 GG polymorphisms were associated with low
lasma holotranscobalamin and high homocysteine in elderly
atino patients. Unfortunately, the effect of genotypes on cogni-
ion was not directly tested (Garrod et al., 2010, 2008). The T776C
olymorphism may  affect the folding of the transcobalamin pro-
ein, possibly reducing afﬁnity for B12, although this proposal has
ot been conclusively tested (Riedel et al., 2011). TCN2 status also
ffects homocysteine levels but it has not been analyzed as exten-
ively as MTHFR.
The methionine reductase (MTR) A2756G polymorphism was
nalyzed in 152 patients with Alzheimer’s disease and 136 con-
rols. Homozygosity for the A allele was associated with greater
everity of dementia, which increased when subjects were also
POE4 or IL-6 CC carriers (Bosco et al., 2004). This potential gene-
ene interaction may  be due to homocysteine’s neurotoxicity via
xidative stress and amyloid beta generation. APOE4 has been
hown to increase amyloid beta levels by reducing brain clearance
ompared to epsilon 2 and 3 (Brown et al., 2011). Other stud-
es have shown no effects of B12 related polymorphisms such as
TR  A2756G genotypes, thymidylate synthase (TS) 2R→3R and ser-
ne hydroxymethyltransferase (SHMT1) 1420C→T  on cognition in
lderly subjects (Bathum et al., 2007; Schiepers et al., 2011).
The glutamate carboxypeptidase (GCPII) C1561T polymorphism
ppears to increase plasma folate and decrease homocysteine, as
ell as scores in the Symbol Digit Modalities Test (SDMT) in aged
orwegians (Halsted et al., 2007). However, no effects of GCPII or
OLH1 genotypes were found for indices of depression or alco-
ol use in this population. Finally, a study in Chinese Alzheimer’s
atients found a very weak association of the MTHFD1 G1958A
 allele for early onset AD, but found no association of the CˇS
44ins68 polymorphism (Bi et al., 2010).
0. Discussion
While many epidemiological studies have shown that B vita-
in deﬁciency is associated with various psychiatric and cognitive
ssues, B vitamin supplementation has had little effect on its own.
ince ‘vulnerability’ genotypes such as MTHFR 677TT have low
requencies in many populations and its effects are subtle, the num-
ers of subjects needed for a B vitamin intervention study, with
ufﬁcient groups of homozygotes, is unfeasible. Yet observational
tudies using cohorts are not appropriate to test whether psychi-
tric and cognition issues are reversible or even caused by changes
n B vitamin intake. Although analyses of variants in several B
itamin metabolic pathways seem promising in genetic associa-
ion studies, the contribution of a single gene or small subset of
enes is not likely to show reproducible effects, due to different
enetic populations or different diets. More consistent intervention
tudy outcomes were observed in subjects with baseline homo-
ysteinuria or other markers of imbalanced methyl donor status,
here genotype status contributes to an imbalance and thus is
menable to correcting levels of nutrients. However, as stated
arlier, selection or stratiﬁcation of subjects based on self-report
uestionnaires or even plasma B vitamins may  not indicate levels
f active forms such as methylcobalamin or methylenetetrahydro-
olate. Thus future studies would be well served by selection of
ubjects with imbalances in active or downstream components of
he methyl donor pathways, like SAM/SAH.havioral Reviews 47 (2014) 307–320 317
Even with some successes in showing genotype contributions,
the value of assessing genetic analysis of behavioral diseases can be
questioned even for those conditions with strong hereditary con-
tributions. In fact, most available studies show negligible effects of
single genes such as MTHFR, MTR and CˇS polymorphisms. While
the MTHFR C677T polymorphism may  mediate signiﬁcant effects
on populations of schizophrenics, it contributes 1–3% to the inci-
dence and 1–3% to the risk of severity. General practitioners, clinical
trial researchers, or health policy analysts would not likely consider
genetic testing or treatment for most psychiatric disease because
of the limited evidence.
A more promising experimental design would be based on
systems biology approaches to map  the synergies of multiple
genotypes in subjects, combined with improved assessments of
nutritional intakes, more exhaustive physiological analyses, and
standardized psychiatric or cognitive testing. Since one carbon
metabolism is involved in many basic processes, the systems
approach might include assessing ‘omics’ or customized panels
relating to nutritional pathways. For instance epigenetic modiﬁ-
cations of many neurodevelopmental genes have been shown to
be attenuated by folic acid and B12 deﬁciencies (Schaevitz and
Berger-Sweeney, 2012). Similarly, MTRR or MTHFR genotypes are
also associated with methylation status of genes involved in neu-
rodevelopment such as IGFBP3 and IGF2 (McKay et al., 2012).
Methyl donor deﬁciency may  strongly impact epigenetic
remodeling during key periods of development, and these epi-
genetic changes are likely intensifying the genetic inﬂuence of
B vitamin genotypes. Indeed, Burghardt and associates reported
that female schizophrenics with MTHFR 677TT genotypes had
the lowest levels of DNA methylation in blood cells, indicating a
possible role of epigenetic contribution to mental illness as well
as comorbidities such as metabolic syndrome (Burghardt et al.,
2012). ‘Hypomethylating’ B vitamin genotypes may  be contribut-
ing to the notable diversity of neurological and psychiatric diseases
linked to one carbon pathway polymorphisms. Depending on com-
plex interactions of environment, diet and genetics, deﬁciencies
in methylation capacity may  give rise to differential changes in
sets of proteins involved in schizophrenia, depression or demen-
tia pathology. However, it must be noted that DNA methylation
status of brain versus peripheral tissue is not consistent, and thus
it will be important to validate mechanisms of nutritional and
epigenetic interactions using animal models. These models could
also incorporate analysis of other epigenetic mechanisms such as
microRNA expression and histone deacetylation (Roth and Sweatt,
2011; Stone et al., 2011).
Translating animal model results to humans may not require
large numbers of participants using systems analyses and n-of-1
experimental approaches (Lillie et al., 2011). These types of studies
require longitudinal analyses with more exhaustive phenotyping
of the participant, but also better analysis of metadata: socioeco-
nomic, psychological history, and other lifestyle measures. The
combination of ‘phenotyping’ data with new strategies such as
middle out analysis methods may  provide a means to better under-
stand complex phenotypes (Majumder and Mukherjee, 2011; de
Graaf et al., 2009). The use of middle out methods can ultimately
focus analysis on an expanded subsystem of genes contributing
to the phenotype studied. For instance, SAM-dependent methyl-
transferases are a large family of enzymes that are unconnected to
each other except for the need of adequate SAMe supplies to func-
tion. COMT is the best known of this genes family and its variants
have been shown to be associated with psychiatric diseases. Poly-
morphisms in other SAM-dependent enzymatic genes would be
expected to have much more severe effects in individuals with B12
or folic acid-related polymorphisms. Besides methyltransferases,
SAM transporters have also not been well-studied for associations
to mental health, thus further research is needed to identify other
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enes which affect SAM bioavailability as well as metabolism, and
pply these sets of genes to clinical outcomes. Although few tri-
ls have applied focused genotyping panels based on particular
athways or families of enzymes, with the pace of technological
dvances in sequencing, even small n studies may  beneﬁts from
hese practices.
One of the difﬁculties of measuring a micronutrient deﬁciency’s
ffect on behavior is the lack of consistent methods for assessing an
ndividual’s needs and responses, since optimal nutrient status will
e different depending on genotype. Genes involved in transport,
uch as transcobalamin 2 (TCN2) may  contribute to less efﬁcient
ptake of vitamin B12, yet standard measures of B12 in plasma may
ot show this deﬁcit, thereby overlooking ‘sufﬁcient’ psychiatric
atients who may  beneﬁt from nutritional therapy. A recent study
emonstrated that serum holoTC, but not plasma vitamin B12,
MA,  or tHcy, varied according to TCN2 67A→G genotype (Riedel
t al., 2011). The contribution of this gene to deﬁciency would not be
ound by focusing on free vitamin B12 levels alone. Another inter-
sting development in nutritional research is the development of
omputational models that may  shed more light on how ﬂuxes of
 vitamin bioavailability proteins will alter propensity for mental
llness risk.
In conclusion, diverse clinical studies have revealed weak
nd in some cases inconsistent associations of cognition,
ood and neurodevelopment disorders to genes involved in
 vitamin metabolism. Use of new experimental models and
esigns, more extensive phenotyping, and more detailed under-
tanding of an individual’s exposures to stress, diet, and
ifestyle will likely improve the consistency and reliability of
enotype–nutrient–behavior interaction data.
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